X Square Capital LLC Makes New $1.91 Million Investment in Teva Pharmaceutical Industries Ltd. $TEVA

X Square Capital LLC purchased a new stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) in the 2nd quarter, Holdings Channel reports. The firm purchased 56,230 shares of the company’s stock, valued at approximately $1,905,000.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Global Retirement Partners LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 27.3% during the 4th quarter. Global Retirement Partners LLC now owns 1,360 shares of the company’s stock worth $42,000 after acquiring an additional 292 shares during the period. Captrust Financial Advisors grew its holdings in Teva Pharmaceutical Industries by 2.1% in the fourth quarter. Captrust Financial Advisors now owns 14,715 shares of the company’s stock valued at $459,000 after purchasing an additional 302 shares during the period. Banque Cantonale Vaudoise grew its holdings in Teva Pharmaceutical Industries by 6.3% in the fourth quarter. Banque Cantonale Vaudoise now owns 5,133 shares of the company’s stock valued at $160,000 after purchasing an additional 306 shares during the period. Ethic Inc. increased its position in Teva Pharmaceutical Industries by 1.8% during the fourth quarter. Ethic Inc. now owns 18,127 shares of the company’s stock worth $566,000 after purchasing an additional 325 shares during the last quarter. Finally, Allworth Financial LP increased its position in Teva Pharmaceutical Industries by 53.8% during the fourth quarter. Allworth Financial LP now owns 941 shares of the company’s stock worth $29,000 after purchasing an additional 329 shares during the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have weighed in on TEVA. JPMorgan Chase & Co. lifted their price target on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company an “overweight” rating in a report on Thursday, April 30th. Barclays upped their price objective on Teva Pharmaceutical Industries from $40.00 to $42.00 and gave the stock an “overweight” rating in a report on Wednesday, August 12th. Piper Sandler increased their target price on Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 28th. Wall Street Zen cut Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Finally, UBS Group boosted their price target on Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the company a “buy” rating in a research report on Thursday, April 30th. Nine analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, Teva Pharmaceutical Industries has a consensus rating of “Moderate Buy” and a consensus price target of $42.22.

Insider Buying and Selling at Teva Pharmaceutical Industries

In related news, EVP Eliyahu Sharon Kalif sold 106,563 shares of Teva Pharmaceutical Industries stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $34.10, for a total transaction of $3,633,798.30. Following the transaction, the executive vice president owned 65,621 shares in the company, valued at approximately $2,237,676.10. The trade was a 61.89% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 0.54% of the company’s stock.

Teva Pharmaceutical Industries Trading Up 1.5%

NYSE TEVA opened at $37.37 on Friday. Teva Pharmaceutical Industries Ltd. has a one year low of $17.82 and a one year high of $37.83. The company’s 50 day moving average price is $33.82 and its 200 day moving average price is $33.13. The company has a debt-to-equity ratio of 1.56, a quick ratio of 0.67 and a current ratio of 0.88. The firm has a market capitalization of $43.55 billion, a price-to-earnings ratio of 62.28, a PEG ratio of 3.99 and a beta of 0.86.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Tuesday, June 30th. The company reported $0.02 earnings per share (EPS) for the quarter. Teva Pharmaceutical Industries had a net margin of 4.08% and a return on equity of 32.64%. The company had revenue of $4.14 billion during the quarter. On average, sell-side analysts predict that Teva Pharmaceutical Industries Ltd. will post 1.96 EPS for the current year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.